CorneaGen announced that James “Jim” C. Wachtman has joined the young company as chief commercial officer. Mr. Wachtman has been a leader in the cornea community for 20 years and serves as the chair of the Refractive Surgery Council, a group of industry manufacturers and ophthalmologists focused on growing the Lasik surgery industry.
Mr. Wachtman will work closely with CorneaGen Chief Technology Officer Bob Stevens to innovate the next generation of cornea care and move CorneaGen forward in its mission to eliminate corneal blindness worldwide.
“Hiring Jim is a strategic step in our effort to diversify CorneaGen’s offering for surgeons and move beyond tissue,” CorneaGen President and CEO Monty Montoya, said in a company news release. “His deep experience in growing opportunities in ophthalmology will help us accomplish our mission.”
Mr. Wachtman’s most recent experience in eyecare was helping to expand the offering of Precision Lens through a mobile femtosecond and cataract service called Precision Eye Services. He previously served as president and CEO of TLC Vision (TLC), a $300 million, publicly held provider of laser vision correction, cataract services and optometric services. Mr. Wachtman was named president and chief operating officer of TLC after its predecessor, Laser Vision Centers (LVCI), was acquired. Mr. Wachtman was also president and chief operating officer of LVCI before the sale.
Mr. Wachtman has served as a venture partner with SV Life Sciences and also worked with Bain Capital Ventures and FTL Capital to develop businesses across medical technologies and healthcare services. He started his 34-year healthcare career at American Hospital Supply (McGaw Division) as a sales representative, rising to the role of vice president of the infusion device division before becoming one of the founding executives of Central Admixture Pharmacy Services, a pharmacy compounding service partnering with large hospital systems and home infusion companies.